Correlation of p16INK4A overexpression with human papillomavirus infection in cervical adenocarcinomas

International Journal of Gynecological Pathology

Volumn 22, Issue 4, 2003, Pages 378-385

  Ishikawa, Mitsuya ^a   Fujii, Takuma ^a   Masumoto, Nobuo ^a   Saito, Miyuki ^a   Mukai, Makio ^a   Nindl, Ingo ^b   Ridder, Ruediger ^b   Fukuchi, Takeshi ^a   Kubushiro, Kaneyuki ^a   Tsukazaki, Katsumi ^a   Nozawa, Shiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MTM Laboratories AG   (Germany)

Author keywords

Adenocarcinoma; Human papillomavirus; P16INK4A; Uterine cervix

Indexed keywords

PROTEIN P16; VIRUS DNA; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN P16INK4A; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; FEMALE; FEMALE GENITAL TRACT INFECTION; GENE OVEREXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; SQUAMOUS CELL CARCINOMA; UPREGULATION; UTERINE CERVIX TUMOR; VIROLOGY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR VIRUS INFECTIONS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 0141569547     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000092135.88121.1f     Document Type: Article

References (44)

1. Fujii T, Tsukazaki K, Kiguchi K, et al. The major E6/E7 transcript of HPV-16 in exfoliated cells from cervical neoplasia patients. Gynecol Oncol 1995;58:210-5.
2. Nakagawa H, Sugano K, Fujii T, et al. Frequent detection of human papilloma viruses in cervical dysplasia by PCR single-strand DNA-conformational polymorphism analysis. Anticancer Res 2002;22:1655-60.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
4. Li Y, Nichols MA, Shay JW, et al. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retino-blastoma susceptibility gene product pRb. Cancer Res 1994;54:6078-82.
5. Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 2000;35:317-29.
6. Parry D, Bates S, Mann DJ, et al. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 1995;14:503-11.
7. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996;65:442-5.
8. Nakao Y, Yang X, Yokoyama M, et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410-6.
9. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Intl J Cancer 2001;92:276-84.
10. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357:1490-3.
11. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 2001;164:1151-2.
12. Takeda N, Sakuragi N, Takeda M, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 2002;81:1144-51.
13. Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 2000;26:464-7.
14. Chen RJ, Lin YH, Chen CA, et al. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999;73:184-90.
15. Fujinaga Y, Shimada M, Okazawa K, et al. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol 1991;72:1039-44.
16. Sasagawa T, Minemoto Y, Basha W, et al. A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV). Virus Res 2000;67:127-39.
17. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995;11:136-40.
18. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
19. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
20. Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Nat Acad Sciences USA 1996;93:4350-4.
21. Nakashima R, Fujita M, Enomoto T, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999;80:458-67.
22. Park JS, Dong SM, Kim HS, et al. Detection of p16 gene alteration in cervical cancer using tissue microdissection and LOH study. Cancer Lett 1999;136:101-8.
23. Yoshinouchi M, Hongo A, Takamoto N, et al. Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines. Intl J Oncol 2000;16:537-41.
24. Kim JW, Namkoong SE, Ryu SW, et al. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol Oncol 1998;70:75-9.
25. Munirajan AK, Kannan K, Bhuvarahamurthy V, et al. The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India. Gynecol Oncol 1998;69:205-9.
26. Sano T, Oyama T, Kashiwabara K, et al. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int 1998;48:580-5.
27. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.
28. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91.
29. Kim YT, Cho NH, Park SW, et al. Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma. Gynecol Oncol 1998;71:38-45.
30. Lu X, Toki T, Konishi I, et al. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer 1998;82:2409-17.
31. Riethdorf L, Riethdorf S, Lee KR, et al. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002;33:899-904.
32. Milde-Langosch K, Riethdorf S, Kraus-Poppinghaus A, et al. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439:55-61.
33. Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and Thin-Prep smears. J Clin Pathol 2003;56:56-63.
34. Lu X, Shiozawa T, Nakayama K, et al. Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. Int J Gynecol Pathol 1999;18:109-14.
35. Negri G, Egarter-Vigl E, Kasal A, et al. p16INK4a Is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and Its precursors: An immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003;27:187-93.
36. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000;15:1055-62.
37. Ferguson AW, Svoboda-Newman SM, Frank TS. Analysis of human papillomavirus infection and molecular alterations in adenocarcinoma of the cervix. Mod Pathol 1998;11:11-8.
38. Lee CT, Capodieci P, Osman I, et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 1999;5:977-83.
39. Bibbo M, Klump WJ, DeCecco J, et al. Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002;46:25-9.
40. Andersson S, Rylander E, Larsson B, et al. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001;37:246-50.
41. Iwasawa A, Nieminen P, Lehtinen M, et al. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 1996;77:2275-9.
42. Vizcaino AP, Moreno V, Bosch FX, et al. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-45.
43. Tase T, Okagaki T, Clark BA, et al. Human papillomavirus types and localization in adenocarcinoma and adenosquamous carcinoma of the uterine cervix: a study by in situ DNA hybridization. Cancer Res 1988;48:993-8.
44. Lee MF, Chang MC, Wu CH. Detection of human papillomavirus types in cervical adenocarcinoma by the polymerase chain reaction. Intl J Gynaecol Obstet 1998;63:265-70.